In other oestrogen-dependent tumours, such as mammary tumours, the inhibition of aromatase activity by aromatase inhibitors is currently one of the first therapeutic strategies used against the growth of these tumours (Kitawaki et al, 1992; Burak et al, 1997). Here, CYP19A1 is linked to neoplasm.